Therefore, in light of our series of in vitro observations in melanoma, we first hypothesized that targeting GHR in melanoma can improve the response of the tumor to anti-cancer drugs by attenuating ABC transporter expression in a pre-clinical mouse model of melanoma. The gene discussed is GHR; the disease is neoplasm.